Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Microbix receives milestone payment under ThromboClear agreement with Gensia

July 25, 1997

Novel fibrinogen/integrin receptor antagonists described by Merck KGaA

July 22, 1997

DuPont Merck prepares anticoagulant aminoboronic acids

July 21, 1997

Fibrinogen-antagonistic oxopiperazine derivatives from Yamanouchi

July 17, 1997

Potent, orally active fibrinogen antagonist developed at Merck & Co.

July 17, 1997

Texas Biotechnology initiates NDA filing for Novastan

July 16, 1997

Merck & Co. develops potent and selective pyridinone acetamide thrombin inhibitor

July 16, 1997

Lp(a)-dependent actions of LMWH

July 14, 1997

Antithrombotic efficacy of TAK-029 in animal models

July 11, 1997

Roberts seeks European approval of Agrylin

July 11, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 8, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 8, 2024.
Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly
BioWorld
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.